Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement : the complexity of the elderly
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissionsoup.com..
Along with epidemiologic transitions of the global population, the burden of aortic stenosis (AS) is rapidly increasing and transcatheter aortic valve replacement (TAVR) has quickly spread; indeed, it is nowadays also employed in treating patients with AS at intermediate operative risk. Nonetheless, the less invasive interventional strategy still carries relevant issues concerning post-procedural optimal antithrombotic strategy, given the current indications provided by guidelines are not completely supported by evidence-based data. Geriatric patients suffer from high bleeding and thromboembolic risks, whose balance is particularly subtle due to the presence of concomitant conditions, such as atrial fibrillation and chronic kidney disease, that make the post-TAVR antithrombotic management particularly insidious. This scenario is further complicated by the lack of specific evidence regarding the 'real-life' complex conditions typical of the geriatric syndromes, thus, the management of such a heterogeneous population, ranging from healthy ageing to frailty, is far from being defined. The aim of the present review is to summarize the critical points and the most updated evidence regarding the post-TAVR antithrombotic approach in the geriatric population, with a specific focus on the most frequent clinical settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
European journal of preventive cardiology - 28(2021), 1 vom: 23. März, Seite 87-97 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bencivenga, Leonardo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.04.2021 Date Revised 12.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/eurjpc/zwaa053 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321824296 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321824296 | ||
| 003 | DE-627 | ||
| 005 | 20231225180719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurjpc/zwaa053 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM321824296 | ||
| 035 | |a (NLM)33624104 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bencivenga, Leonardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement |b the complexity of the elderly |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2021 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a Along with epidemiologic transitions of the global population, the burden of aortic stenosis (AS) is rapidly increasing and transcatheter aortic valve replacement (TAVR) has quickly spread; indeed, it is nowadays also employed in treating patients with AS at intermediate operative risk. Nonetheless, the less invasive interventional strategy still carries relevant issues concerning post-procedural optimal antithrombotic strategy, given the current indications provided by guidelines are not completely supported by evidence-based data. Geriatric patients suffer from high bleeding and thromboembolic risks, whose balance is particularly subtle due to the presence of concomitant conditions, such as atrial fibrillation and chronic kidney disease, that make the post-TAVR antithrombotic management particularly insidious. This scenario is further complicated by the lack of specific evidence regarding the 'real-life' complex conditions typical of the geriatric syndromes, thus, the management of such a heterogeneous population, ranging from healthy ageing to frailty, is far from being defined. The aim of the present review is to summarize the critical points and the most updated evidence regarding the post-TAVR antithrombotic approach in the geriatric population, with a specific focus on the most frequent clinical settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antithrombotic therapy | |
| 650 | 4 | |a Aortic stenosis | |
| 650 | 4 | |a Atrial fibrillation | |
| 650 | 4 | |a Autonomic dysfunction | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Geriatric syndromes | |
| 650 | 4 | |a TAVR | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Sepe, Immacolata |e verfasserin |4 aut | |
| 700 | 1 | |a Palaia, Maria Emiliana |e verfasserin |4 aut | |
| 700 | 1 | |a Komici, Klara |e verfasserin |4 aut | |
| 700 | 1 | |a Corbi, Graziamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Puzone, Brunella |e verfasserin |4 aut | |
| 700 | 1 | |a Arcopinto, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Cittadini, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Femminella, Grazia Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Rengo, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of preventive cardiology |d 2012 |g 28(2021), 1 vom: 23. März, Seite 87-97 |w (DE-627)NLM19817909X |x 2047-4881 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2021 |g number:1 |g day:23 |g month:03 |g pages:87-97 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurjpc/zwaa053 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2021 |e 1 |b 23 |c 03 |h 87-97 | ||